Immunohistochemical and biochemical expression patterns of TTF-1, RAGE, GLUT-1 and SOX2 in HCV-associated hepatocellular carcinomas

Show simple item record

dc.contributor.author Aboushousha T.
dc.contributor.author Mamdouh S.
dc.contributor.author Hamdy H.
dc.contributor.author Helal N.
dc.contributor.author Khorshed F.
dc.contributor.author Safwat G.
dc.contributor.author Seleem M.
dc.contributor.other Pathology Departmenty
dc.contributor.other
dc.contributor.other Giza
dc.contributor.other Egypt; Biochemistry Departmenty
dc.contributor.other
dc.contributor.other Giza
dc.contributor.other Egypt; Surgical Department
dc.contributor.other Theodor Bilharz Research Institutey
dc.contributor.other
dc.contributor.other Giza
dc.contributor.other Egypt; Faculty of Biotechnology
dc.contributor.other
dc.contributor.other Giza
dc.contributor.other Egypt; National Hepatology and Tropical Medicine Research Institute
dc.contributor.other Cairo
dc.contributor.other Egypt
dc.date.accessioned 2020-01-09T20:41:03Z
dc.date.available 2020-01-09T20:41:03Z
dc.date.issued 2018
dc.identifier.issn 15137368
dc.identifier.other https://doi.org/10.22034/APJCP.2018.19.1.219
dc.identifier.other PubMedID29373917
dc.identifier.uri https://t.ly/lWWGB
dc.description Scopus
dc.description MSA Google Scholar
dc.description.abstract Objective: To investigate the expression of TTF-1, RAGE, GLUT1 and SOX2 in HCV-associated HCCs and in surrounding non-tumorous liver tissue. Material and Methods: Tissue material from partial hepatectomy cases for HCC along with corresponding serum samples and 30 control serum samples from healthy volunteers were studied. Biopsies were classified into: non-tumor hepatic tissue (36 sections); HCC (33 sections) and liver cell dysplasia (LCD) (15 sections). All cases were positive for HCV. Immunohistochemistry (IHC), gene extraction and quantitative real-time reverse-transcription assays (qRT-PCR) were applied. Results: By IHC, LCD and HCC showed significantly high percentages of positive cases with all markers. SOX2 showed significant increase with higher HCC grades, while RAGE demonstrated an inverse relation and GLUT-1 and TTF-1 lacked any correlation. In nontumorous-HCV tissue, we found significantly high TTF-1, low RAGE and negative SOX2 expression. RAGE, GLUT-1 and SOX2 show non-significant elevation positivity in high grade HCV compared to low grade lesions. TTF-1, RAGE and SOX2 exhibited low expression in cirrhosis compared to fibrosis. Biochemical studies on serum and tissue extracts revealed significant down-regulation of RAGE, GLUT-1 and SOX2 genes, as well as significant up-regulation of the TTF-1 gene in HCC cases compared to controls. All studied genes show significant correlation with HCC grade. In non-tumor tissue, only TTF-1 gene expression had a significant correlation with the fibrosis score. Conclusion: Higher expression of TTF-1, RAGE, GLUT-1 and SOX2 in HCC and dysplasia compared to non-tumor tissues indicates up-regulation of these markers as early events during the development of HCV-associated HCC. en_US
dc.language.iso English en_US
dc.publisher Asian Pacific Organization for Cancer Prevention en_US
dc.relation.ispartofseries Asian Pacific Journal of Cancer Prevention
dc.relation.ispartofseries 19
dc.subject GLUT1 en_US
dc.subject HCC en_US
dc.subject HCV en_US
dc.subject IHC en_US
dc.subject RAGE en_US
dc.subject SOX2 en_US
dc.subject TTF1 en_US
dc.title Immunohistochemical and biochemical expression patterns of TTF-1, RAGE, GLUT-1 and SOX2 in HCV-associated hepatocellular carcinomas en_US
dc.type Article en_US
dcterms.isReferencedBy Agoff, S.N., Lamps, L.W., Philip, A.T., Thyroid transcription factor-1 is expressed in extrapulmonary small cell carcinomas but not in other extrapulmonary neuroendocrine tumors (2000) Mod Pathol, 13, pp. 238-242; Airley, R.E., Mobasheri, A., Hypoxic regulation of glucose transport, anaerobic metabolism and angiogenesis in cancer: novel pathways and targets for anticancer therapeutics (2007) Chemotherapy, 53, pp. 233-256; Amann, T., Maegdefrau, U., Hartmann, A., GLUT-1 expression is increased in hepatocellular carcinoma and promotes tumorigenesis (2009) Am J Pathol, 174, pp. 1544-1552; Basu-Roy, U., Seo, E., Ramanathapuram, L., Sox2 maintains self renewal of tumor-initiating cells in osteosarcomas (2012) Oncogene, 31, pp. 2270-2282; Blechacz, B., Mishra, L., Hepatocellular carcinoma biology (2013) Recent Results Cancer Res, 190, pp. 1-20; Bosman, F.T., Carneiro, F., Hruban, R.H., Theise, N.D., Tumours of the liver and intrahepatic bile ducts (2010) In 'pathology and genetics of tumors of the digestive system', pp. 205-216. , Eds International Agency for Research on Cancer, Lyon; Boyer, L.A., Lee, T.I., Cole, M.F., Core transcriptional regulatory circuitry in human embryonic stem cells (2005) Cell, 122, pp. 947-956; Cao, Q., Liu, F., Xiao, P., Cytoplasmic staining of TTF-1 antibody in the diagnosis of hepatocellular carcinoma: study on 299 cases using tissue microarray (2011) ISRN Pathol, 7; Chen, S., Mandavilli, S., Mandich, D., Perkins, M.L., Cartun, R.W., Value of thyroid transcription factor (TTF-1) and anti-hepatocyte monoclonal antibodies in differentiating hepatocellular carcinoma (HCC) from metastatic adenocarcinoma (MA) in liver (2001) Mod Pathol, 14, p. 1138; Chen, C., Pore, N., Behrooz, A., Ismail-Beigi, F., Maity, A., Regulation of glut-1 mRNA by hypoxia inducible factor-1 (2001) J Biol Chem, 276, pp. 9519-9525; Comp�rat, E., Zhang, F., Perrotin, C., Variable sensitivity and specificity of TTF-1 antibodies in lung metastatic adenocarcinoma of colorectal origin (2005) Mod Pathol, 18, pp. 1371-1376; Czech, B., Valletta, D., Saugspier, M., Effect of increased glucose transporter 1 (GLUT-1) expression in activated hepatic stellate cells (2013) Z Gastroenterol, 51, pp. 1-10; Czech, B., Valletta, D., M�ller, M., Bosserhoff, A., Hellerbrand, C., Expression and function of glucose transporter 1 (GLUT-1) expression in activated hepatic stellate cells (2014) Z Gastroenterol, 52, pp. 1-15; El-Tayeha, S.F., Husseina, T.D., El-Houseini, M.E., Serological biomarkers of hepatocellular carcinoma in Egyptian patients (2012) Dis Markers, 32, pp. 255-263; Fang, X., Yu, W., Li, L., ChIP-seq and functional analysis of the SOX2 gene in colorectal cancers (2010) OMICS, 14, pp. 369-384; Fang, X., Yoon, J.G., Li, L., The SOX2 response program in glioblastoma multiforme: an integrated ChIPseq, expression microarray, and microRNA analysis (2011) BMC Genomics, 12, pp. 11-28; Folpe, A.L., Gown, M.D., Lamps, L.W., Thyroid transcription factor-1: immunohistochemical evaluation in pulmonary neuroendocrine tumors (1999) Mod Pathol, 12, pp. 5-8; Forner, A., Llovet, J.M., Bruix, J., Hepatocellular carcinoma (2012) Lancet, 379, pp. 1245-1255; Gatenby, R.A., Smallbone, K., Maini, P.K., Cellular adaptations to hypoxia and acidosis during somatic evolution of breast cancer (2007) Br J Cancer, 97, pp. 646-653; Gokden, M., Shinde, A., Recent immunohistochemical markers in the differential diagnosis of primary and metastatic carcinomas of the liver (2005) Diag Cytopathol, 33, pp. 166-172; Gomaa, A.I., Hashim, M.S., Waked, I., Comparing staging systems for predicting prognosis and survival in patients with hepatocellular carcinoma in Egypt (2014) PLoS One, 9; Han, X., Fang, X., Lou, X., Silencing SOX2 induced mesenchymal-epithelial transition and its expression predicts liver and lymph node metastasis of CRC patients (2012) PLoS One, 7; Hiwatashi, K., Ueno, S., Abeyama, K., A novel function of the receptor for advanced glycation end-products (RAGE) in association with tumorigenesis and tumor differentiation of HCC (2007) Ann Surg Oncol, 15, pp. 923-933; Huang, P., Qiu, J., Li, B., Role of Sox2 and Oct4 in predicting survival of hepatocellular carcinoma patients after hepatectomy (2011) Clin Biochem, 44, pp. 582-589; Ito, R., Ishii, Y., Wakiyama, S., Prognostic significance of receptor for advanced glycation end products expression in hepatocellular carcinoma after hepatectomy (2014) J Surg Res, 192, pp. 503-508; Kang, S.S., Chun, Y.K., Hur, M.H., Clinical significance of glucose transporter 1 (GLUT-1) expression in human breast carcinoma (2002) Jpn J Cancer Res, 93, pp. 1123-1128; Kim, W.S., Kim, Y.Y., Jang, S.J., Kimm, K., Jung, M.H., Glucose transporter 1 (GLUT-1) expression is associated with intestinal type of gastric carcinoma (2000) J Korean Med Sci, 15, pp. 420-424; Krzeslak, A., Wojcik-Krowiranda, K., Forma, E., Expression of GLUT-1 and GLUT3 Glucose Transporters in Endometrial and Breast Cancers (2012) Pathol Oncol Res, 18, pp. 721-728; Lei, J.Y., Bourne, P.A., diSant'Agnese, P.A., Huang, J., Cytoplasmic staining of TTF-1 in the differential diagnosis of hepatocellular carcinoma vs cholangiocarcinoma and metastatic carcinoma of the liver (2006) Am J Clin Pathol, 125, pp. 519-525; Li, X.L., Eishi, Y., Bai, Y.Q., Expression of the SRYrelated HMG box protein SOX2 in human gastric carcinoma (2004) Int J Oncol, 24, pp. 257-263; Mano, Y., Ishima, S., Kubo, Y., Correlation between biological marker expression and fluorine-18 fluorodeoxyglucose uptake in hepatocellular carcinoma (2014) Am J Clin Pathol, 142, pp. 391-397; Medina, R.A., Owen, G.I., Glucose transporters: expression, regulation and cancer (2002) Biol Res, 35, pp. 9-26; (2015) Egypt Health Issues Survey 2015, , Cairo, Egypt and Rockville, Maryland, USA: Ministry of Health and Population and ICF International; Mokhtar, N., Gouda, I., Adel, I., Malignant digestive system tumors (2007) In Cancer pathology registry 2003-2004 and time trend analysis, pp. 55-67. , Eds Mokhtar N, Gouda I, Adel I. Elsheraa Press, Cairo, Egypt; Nedic, O., Rattan, S.I.S., Grune, T., Trougakos, I.P., Molecular effects of advanced glycation end products on cell signaling pathways, ageing and pathophysiology (2013) Free Radic Res, 47, pp. 28-38; Poynard, T., Ratziu, V., Benmanov, Y., Fibrosis in patients with hepatitis c: detection and significance: detection and significance (2000) Semin Liver Dis, 20, pp. 47-55; Pusterla, T., N�meth, J., Stein, I., Receptor for advanced glycation end products (RAGE) is a key regulator of oval cell activation and inflammation-associated liver carcinogenesis in mice (2013) Hepatology, 58, pp. 363-373; Rodriguez-Pinilla, S.M., Sarrio, D., Moreno-Bueno, G., Sox2: a possible driver of the basal-like phenotype in sporadic breast cancer (2007) Mod Pathol, 20, pp. 474-481; Sanada, Y., Yoshida, K., Ohara, M., Histopathologic evaluation of stepwise progression of pancreatic carcinoma with immunohistochemical analysis of gastric epithelial transcription factor SOX2: comparison of expression patterns between invasive components and cancerous or nonneoplastic intraductal components (2006) Pancreas, 32, pp. 164-170; Shaker, M.K., Abdella, H.M., Khalifa, M.O., Dorry, A.K.E., Epidemiological characteristics of hepatocellular carcinoma in Egypt: a retrospective analysis of 1313 cases (2013) Liver Int, 33, pp. 1601-1606; Sherman, M., Hepatocellular carcinoma: epidemiology, surveillance, and diagnosis (2010) Semin Liver Dis, 30, pp. 3-16; Siegel, R., Naishadham, D., Jemal, A., Cancer statistics (2012) CA Cancer J Clin, 62, pp. 10-294; Forner, A., Llovet, J.M., Bruix, J., Hepatocellular carcinoma (2012) Lancet, 379, pp. 1245-1255; Smith, T.A., Facilitative glucose transporter expression in human cancer tissue (1999) Br J Biomed Sci, 56, pp. 285-292; Sun, C., Sun, L., Li, Y., Sox2 expression predicts poor survival of hepatocellular carcinoma patients and it promotes liver cancer cell invasion by activating Slug (2013) Med Oncol, 30, pp. 503-512; Vlassara, H., Brownlee, M., Cerami, A., Advanced non-enzymatic tissue glycosylation: biochemical basis of late diabetic complications (1989) In diabetes mellitus: pathophysiology and therapy, pp. 209-217. , Eds Creutzfeldt W, Lef�bvre PJ. Springer, Berlin, Heidelberg; Waghray, A., Murali, A.R., Menon, K.N., Hepatocellular carcinoma: From diagnosis to treatment (2015) World J hepatol, 7, pp. 1020-1029; Wieczorek, T.J., Pinkus, J.L., Glickman, J.N., Pinkus, G.S., Comparison of thyroid transcription factor-1 and hepatocyte antigen immunohistochemical analysis in the differential diagnosis of hepatocellular carcinoma, metastatic adenocarcinoma, renal cell carcinoma, and adrenal cortical carcinoma (2002) Am J Clin Pathol, 118, pp. 911-921; Xu, X.C., Abuduhadeer, X., Zhang, W.B., Knockdown of RAGE inhibits growth and invasion of gastric cancer Cells (2013) Eur J Histochem, 29, pp. 240-246; Yamagishi, S., Matsui, T., Role of receptor for advanced glycation end products (RAGE) in liver disease (2015) Eur J Med Res, 20, pp. 15-22; Yilmaz, Y., Onen, H.I., Alp, E., Menevse, S., Real-time PCR for gene expression analysis (2012) In biochemistry, genetics and molecular biology "Polymerase chain reaction", pp. 229-254. , http://cdn.intechopen.com/pdfs-wm/37270.pdf, Eds Hernandez-Rodriguez P and Gomez AP, In Tech publisher, Rijeka, Croatia, [cit. 2014-07-10]; Yin, X., Li, Y., Jin, J., The clinical and prognostic implications of pluripotent stem cell gene expression in hepatocellular carcinoma (2013) Oncol Lett, 5, pp. 1155-1162; Yu, J., Vodyanik, M.A., Smuga-Otto, K., Induced pluripotent stem cell lines derived from human somatic cells (2007) Science, 318, pp. 1917-1920; Zhao, X., Sun, B., Sun, D., Slug promotes hepatocellular cancer cell progression by increasing sox2 and nanog expression (2015) Oncol Rep, 33, pp. 149-156
dcterms.source Scopus
dc.identifier.doi https://doi.org/10.22034/APJCP.2018.19.1.219
dc.identifier.doi PubMedID29373917
dc.Affiliation October University for modern sciences and Arts (MSA)


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search MSAR


Advanced Search

Browse

My Account